AMLX - Amylyx Pharmaceuticals - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AMLX is currently covered by 7 analysts with an average price target of $12.95. This is a potential upside of $4.92 (61.27%) from yesterday's end of day stock price of $8.03.

Amylyx Pharmaceuticals's activity chart (see below) currently has 38 price targets and 55 ratings on display. The stock rating distribution of AMLX is 72.41% BUY and 27.59% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 40.46% with an average time for these price targets to be met of 163.63 days.

Highest price target for AMLX is $16, Lowest price target is $8, average price target is $10.71.

Most recent stock forecast was given by CHRIS SHIBUTANI from GOLDMAN SACHS on 10-Jul-2025.

Currently out of the existing stock ratings of AMLX, 21 are a BUY (72.41%), 8 are a HOLD (27.59%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$2 (25.00%)

$4

1 months 10 days ago
(10-Jul-2025)

4/8 (50%)

$2.61 (35.32%)

178

Buy

$12

$4 (50.00%)

2 months 3 days ago
(17-Jun-2025)

1/3 (33.33%)

$6.67 (125.14%)

188

Buy

$8

$7

3 months 6 days ago
(14-May-2025)

3/5 (60%)

$3.65 (83.91%)

95

Buy

$16

$8 (100.00%)

$12

3 months 11 days ago
(09-May-2025)

9/21 (42.86%)

$11.39 (247.07%)

292

Hold

$10

$2 (25.00%)

3 months 13 days ago
(07-May-2025)

1/4 (25%)

$5.13 (105.34%)

187

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AMLX (Amylyx Pharmaceuticals) average time for price targets to be met?

On average it took 163.63 days on average for the stock forecasts to be realized with a an average price target met ratio 40.46

Which analyst has the current highest performing score on AMLX (Amylyx Pharmaceuticals) with a proven track record?

NEENA BITRITTO-GARG

Which analyst has the current lower performing score on AMLX (Amylyx Pharmaceuticals) with a proven track record?

GEOFF MEACHAM

Which analyst has the most public recommendations on AMLX (Amylyx Pharmaceuticals)?

Neena Bitritto-Garg has 11 price targets and 6 ratings on AMLX

Which analyst is the currently most bullish on AMLX (Amylyx Pharmaceuticals)?

Andrew Fein with highest potential upside - $8

Which analyst is the currently most reserved on AMLX (Amylyx Pharmaceuticals)?

Graig Suvannavejh with lowest potential downside - -$0

Amylyx Pharmaceuticals in the News

Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline

Earnings Call Insights: Amylyx Pharmaceuticals (AMLX) Q2 2025 MANAGEMENT VIEW * Co-CEO Justin B. Klee highlighted “meaningful progress across our clinical programs” in the first half of 2025, emphasizing Avexitide as the lead asset, which is an investigational GLP-1 receptor antagonist for postbariatric hypoglycemia (PBH) with FDA breakthrough therapy designation. Klee stated, “In April, we...

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Q2 2025 Earnings: EPS In Line, Revenue at $0, Market Reaction Muted

AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX [https://www.chartmill.com/stock/quote/AMLX]) REPORTS Q2 2025 EARNINGS: EPS IN LINE, MARKET REACTION MUTED Amylyx Pharmaceuticals Inc released its second-quarter 2025 financial results, posting a net loss of $41.4 million, or $0.46 per share, aligning closely with analyst expectations of a $0.454 loss per share. Revenue for the quarter was reported at $0, also...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?